Human Effect Matrix
Evidence-ranked outcomes from human trials only. Effect direction, strength, and tier shown for each outcome area.
| Outcome | Effect | Strength | Evidence | Key Study |
|---|---|---|---|---|
| Cardiovascular EventsMACE: heart attack, stroke, CV death | ↓ 25% | Strong | Human RCT | REDUCE-IT (8,179 pts, 4g EPA, 4.9yr) |
| All-Cause MortalityTotal deaths in trial populations | ↓ 20% | Strong | GISSI-Prevenzione + meta-analysis | |
| TriglyceridesBlood triglyceride levels | ↓ 15–30% | Strong | Dose-dependent; 2–4g/day | |
| Heart Attack RiskNon-fatal MI in non-fish eaters | ↓ 28% | Moderate | Human RCT | VITAL trial (25,871 pts) |
| Sudden Cardiac DeathArrhythmia-related mortality | ↓ 45% | Moderate | Human RCT | GISSI-Prevenzione 1999 |
| Cognitive FunctionMemory, processing in MCI | ↑ Modest | Preliminary | Human RCT | MIDAS trial (DHA, 24 weeks) |
| Blood PressureSystolic / diastolic | ↓ Small | Moderate | Effect modest; ~1–2 mmHg | |
| Inflammation (CRP)Systemic inflammatory markers | ↓ Modest | Preliminary | Effect inconsistent across trials |
Landmark Clinical Trials
Only Tier A evidence — replicated RCTs with hard endpoints (mortality, MACE, hospitalization)
| Trial | N (Participants) | Dose | Duration | Primary Finding |
|---|---|---|---|---|
| REDUCE-IT (2018) | 8,179 | 4g icosapentaenoic acid (EPA) | 4.9 years | −25% major adverse CV events vs. placebo |
| STRENGTH (2020) | 13,078 | 4g EPA+DHA carboxylic acid | 3.5 years | Neutral on CV events; confirmed tolerance |
| VITAL (2018) | 25,871 | 1g fish oil/day | 5.3 years | −28% heart attack risk in non-fish eaters; −17% MI overall |
| ASCEND (2018) | 15,480 | 1g EPA+DHA | 7.4 years | −11% vascular events (non-significant primary); vascular composite improved |
| OMEGA-REMODEL (2016) | 360 | 4g EPA+DHA | 6 months post-MI | −5.6% LV end-systolic volume; preserved ejection fraction post-MI |
| MIDAS (2010) | 485 | 1.86g DHA | 24 weeks | −26.7% hippocampal DHA; improved cognitive z-scores in MCI |
| GISSI-Prevenzione (1999) | 11,324 | 1g EPA+DHA | 3.5 years | −20% all-cause mortality, −45% sudden cardiac death |
EPA/DHA are incorporated into phospholipid membranes of cardiomyocytes, stabilizing ion channels. They reduce TG synthesis, lower VLDL secretion, and shift eicosanoid production toward anti-inflammatory resolvins and protectins.
DHA constitutes 40% of brain polyunsaturated fatty acids. Longitudinal data links higher plasma DHA to −47% risk of all-cause dementia (Framingham Heart Study, 22-year follow-up, n=899).
EPA and DHA compete with arachidonic acid for COX-2 and LOX-5 enzymes, reducing production of Series-2 prostaglandins and Series-4 leukotrienes — the primary mediators of chronic systemic inflammation.
A 4-month RCT (n=106, Kiecolt-Glaser 2013) found that omega-3 supplementation increased telomerase activity and was associated with longer telomeres — a direct molecular aging biomarker.
Dosing Protocol
Optimized for longevity and cardiovascular protection — based on REDUCE-IT and VITAL dosing data
Evidence-Based Dosing
⚠ Safety Considerations
At doses ≥3g/day, consult a physician if taking blood thinners (warfarin, aspirin). Fish oil can modestly increase LDL-C in some individuals at high doses — monitor lipid panel. High-dose EPA-only (4g) showed increased atrial fibrillation in REDUCE-IT (3% vs. 2.1%) — discuss with cardiologist. Well-tolerated in otherwise healthy adults at 1–2g/day.
Best Products by Evidence
Curated from 13 leading brands — evaluated on form purity, EPA:DHA ratio, oxidation testing, and third-party certification
Gold standard in omega-3 purity testing. Triglyceride form consistently outperforms ethyl esters in absorption studies by 50–70%.
Get on Fullscript ↗Highest EPA concentration per serving — ideal for the REDUCE-IT cardiovascular protocol. NSF certification means tested for banned substances.
Get on Fullscript ↗Best value per gram of EPA+DHA in TG form. Reliable quality at a lower price point — good for maintenance dosing of 1–2g/day.
Get on Fullscript ↗- Human RCTBhatt et al. NEJM 2019 — REDUCE-IT trial (icosapentaenoic acid and CV events)
- Human RCTManson et al. NEJM 2019 — VITAL trial (omega-3 arm)
- Del Gobbo et al. JAMA Intern Med 2016 — EPA+DHA and coronary heart disease meta-analysis
- Human RCTYokoyama et al. Lancet 2007 — JELIS trial: EPA and cardiovascular events
- ReviewCalder 2020 Nutrients — omega-3 mechanisms review